17 June 2026 | Santosh Hospitals

World Sickle Cell Day falls on June 19 a date chosen by the United Nations in 2008 to acknowledge a condition that is simultaneously one of the most common serious genetic disorders in the world and one of the most inadequately resourced. Sickle cell disease affects an estimated 300,000 newborns annually, the majority in sub-Saharan Africa and South Asia, and India carries one of the highest global burdens of the trait and the disease. For families managing it, the challenge is rarely a shortage of determination it is a shortage of specialist knowledge at the point of care: what triggers a crisis, how organ damage accumulates silently between crises, which interventions actually change the disease course rather than just managing symptoms, and when the conversation about curative treatment should happen and with whom. A Best Sickle Cell Specialist Doctor who understands the disease across its full clinical arc, not just the acute pain episode,, manages it differently from a generalist who sees SCD occasionally. A treatment for sickle cell disease with structured protocols and a specialist team to implement them produces different outcomes from one treating it as a haematological curiosity between other priorities. A top haematology hospital in Delhi NCR with a dedicated blood disorder doctor provides access to the full range of treatment options, including curative ones.

What Sickle Cell Disease Is — and Why the Genetics Matter

Haemoglobin is the protein inside red blood cells that binds oxygen in the lungs and releases it in the tissues. Normal adult haemoglobin (HbA) has a specific molecular structure that allows red cells to remain flexible and biconcave able to squeeze through capillaries smaller than the cell itself. In sickle cell disease, a single point mutation in the beta-globin gene a substitution of valine for glutamic acid at position 6 produces haemoglobin S (HbS). When HbS is deoxygenated, it polymerises into rigid fibres that distort the cell into the characteristic crescent or sickle shape.

The disease requires two abnormal genes one from each parent. A person with one HbS gene and one normal HbA gene has sickle cell trait (HbAS): they are carriers, are generally asymptomatic, and can pass the gene to their children. The disease itself manifests in several genotypes. HbSS (homozygous sickle cell anaemia) is typically the most severe. HbSC disease involves one HbS gene and one HbC gene and tends to be milder but still produces significant complications. Sickle beta-thalassaemia combines HbS with beta-thalassaemia and has variable severity depending on whether beta-globin production is absent (β⁰) or reduced (β⁺). Understanding which genotype a patient has is the starting point for appropriate care at an advanced haematology care hospital in Ghaziabad because severity, monitoring intervals, and treatment thresholds differ meaningfully across these variants.

How Sickle Cell Disease Damages the Body Over Time

Vaso-occlusive crises

The acute pain crisis, also called a vaso-occlusive crisis (VOC), is the most common reason for hospital admission in SCD. It occurs when sickled cells adhere to the vascular endothelium and to each other, blocking small blood vessels and causing ischaemia in the tissues downstream. The pain can be severe enough to require parenteral opioids and is often undertreated in emergency settings where clinicians unfamiliar with SCD apply general acute pain protocols that are inadequate for the intensity and mechanism involved. A Best Blood Disorder Doctor in Delhi NCR who manages SCD regularly has a specific VOC protocol defined analgesic escalation, hydration targets, and monitoring for acute chest syndrome — rather than improvising around a general pain pathway.

Acute chest syndrome

Acute chest syndrome (ACS) is the leading cause of death in adults with sickle cell disease and one of the most dangerous complications of a VOC. It is defined by a new pulmonary infiltrate on chest X-ray combined with respiratory symptoms chest pain, fever, cough, hypoxia and can develop during a hospitalisation for an uncomplicated pain crisis. The mechanism involves fat emboli from infarcted bone marrow, in-situ sickling in pulmonary vessels, and infection. Management includes oxygen, exchange transfusion (not simple transfusion), antibiotics, bronchodilators, and escalation to mechanical ventilation in severe cases. The distinction between ACS and pneumonia is clinically important and not always obvious it requires a specialist making active judgements rather than applying a general respiratory protocol.

Stroke

Children with HbSS have an approximately 11% lifetime risk of clinically apparent stroke by age 20, and the risk of silent cerebral infarction small areas of ischaemic damage that produce no acute neurological symptoms but accumulate cognitive deficits over years is even higher. Transcranial Doppler (TCD) ultrasound measures blood flow velocity in the cerebral arteries and identifies children at high stroke risk before the event occurs. Children with high TCD velocities above 200 cm/s require regular blood transfusion programmes to maintain HbS below 30%, reducing stroke risk by approximately 90%. This screening programme is evidence-based but it requires a top haematology hospital in Delhi NCR with TCD capability and haematological expertise to implement the transfusion programme that follows a high-risk result.

Organ damage accumulating silently

The organs most affected by chronic sickling-related ischaemia are the spleen, kidneys, liver, and eyes. Functional asplenia where the spleen is progressively destroyed by repeated infarction typically develops in HbSS patients by the end of childhood, leaving them permanently vulnerable to encapsulated bacterial organisms including Streptococcus pneumoniae and Haemophilus influenzae. This is why daily penicillin prophylaxis from diagnosis, pneumococcal vaccination, and education of parents about fever management are standard of care from infancy and why an acute febrile illness in an asplenic SCD patient is a medical emergency rather than a wait-and-see situation.

Sickle cell nephropathy begins with hyperfiltration in childhood and progresses to proteinuria, hypertension, and in 30% of HbSS adults, chronic kidney disease. Annual urine albumin-to-creatinine ratio and eGFR monitoring from early adolescence allows intervention before significant irreversible damage occurs. Proliferative sickle retinopathy abnormal new blood vessel formation in the peripheral retina is more prevalent in HbSC than HbSS and produces no symptoms until vitreous haemorrhage or retinal detachment occurs. Annual fundal screening is the only way to identify it before it causes vision loss.

Treatment From Symptom Management to Cure

Hydroxyurea

Hydroxyurea is the most important disease-modifying therapy available for most SCD patients. It works primarily by increasing foetal haemoglobin (HbF) production. HbF does not participate in sickling polymer formation, so higher HbF levels reduce the proportion of HbS available to polymerise. Clinical trial data shows that hydroxyurea reduces VOC frequency by approximately 50%, reduces acute chest syndrome episodes, reduces the need for transfusion, and reduces mortality. It is underused partly due to concerns about teratogenicity and long-term safety that are not supported by the evidence in standard dosing and partly because it requires regular monitoring and dose titration over months to reach optimal HbF response. A top sickle cell specialist in Ghaziabad managing a patient on hydroxyurea reviews the full blood count, reticulocyte count, and HbF level at regular intervals and adjusts the dose to the maximum tolerated rather than stopping at a fixed starting dose.

Transfusion therapy

Simple top-up transfusion increases total haemoglobin and reduces symptoms of anaemia. Exchange transfusion removing the patient's blood while replacing it with donor blood reduces the percentage of HbS specifically and is the appropriate intervention for ACS, acute stroke, and pre-operative preparation in high-risk surgeries. Chronic transfusion programmes targeting HbS below 30% are used for primary and secondary stroke prevention. Iron overload from chronic transfusion requires chelation therapy deferasirox orally or desferrioxamine by infusion and monitoring of serum ferritin and liver iron concentration.

Stem cell transplantation

Allogeneic haematopoietic stem cell transplantation (HSCT) from a matched sibling donor is the only established curative treatment for SCD and produces disease-free survival rates above 90% in children transplanted before significant organ damage has accumulated. The barrier is donor availability only approximately 15% of SCD patients have a matched sibling. Matched unrelated donor and haploidentical transplantation are active areas of clinical development. Gene therapy using the patient's own stem cells with a corrected beta-globin gene has produced promising early results in clinical trials and may become the curative option for patients without a matched donor within the next decade. Access to these options requires a sickle cell disease treatment hospital in Ghaziabad or a referral network with active transplant capability.

Expert Tips for Patients and Families Living with SCD

• Establish care with a haematologist before the next crisis, not during one. Emergency department management of a VOC is reactive — pain control, hydration, monitoring for ACS. A haematologist who knows the patient's baseline, crisis pattern, medications, and organ function history manages the admission differently and catches complications earlier. If you are managing SCD in the Ghaziabad or Delhi NCR area without a specialist, establishing that relationship at a top haematology hospital in Delhi NCR before the next acute episode is the single most impactful step available.
• Hydration is a daily management requirement, not just a crisis response. Dehydration concentrates the blood and increases the viscosity that promotes sickling. SCD adults should aim for 3 to 4 litres of fluid per day in normal conditions more in hot weather or during physical activity. This is not optional lifestyle advice; it is a direct sickling prevention measure.
• Know the signs of acute chest syndrome and treat it as an emergency. A VOC accompanied by new fever, chest pain, or oxygen saturation below 95% is no longer a simple pain crisis. ACS develops rapidly, and the intervention window, including exchange transfusion, is narrow. Do not wait to see if chest symptoms resolve on their own.
• Vaccinations are not optional in SCD they are functional asplenia management. Pneumococcal (PCV13 and PPSV23), meningococcal (MenACWY and MenB), Haemophilus influenzae type b, and annual influenza vaccination are the minimum schedule for an asplenic SCD patient. An advanced haematology care hospital should maintain a vaccination record as part of every SCD patient's standard care plan.
• Ask specifically about hydroxyurea if it has not been offered. Hydroxyurea is appropriate for most HbSS and HbSβ⁰ patients with more than two to three VOCs per year, any episode of ACS, or evidence of progressive organ damage. If it has not been discussed, the question is worth raising directly the evidence base is established, and the safety profile in standard dosing is well-characterised.
• Arrange annual organ screening proactively, not symptomatically. TCD ultrasound for stroke risk in children, annual ophthalmology review for retinopathy, urine albumin for nephropathy, and echocardiography for pulmonary hypertension these screens detect complications that are either asymptomatic until advanced or treatable only when caught early. A Best Blood Disorder Doctors in Delhi NCR managing SCD comprehensively should maintain a structured annual review schedule rather than wait for organ complications to present clinically.
• Have the conversation about curative options early, not as a last resort. Stem cell transplantation is most effective before significant organ damage has accumulated, which means childhood, not adulthood. Sibling matching should occur as part of early family counselling, not when a patient presents in crisis at 35 with established nephropathy. A specialist who raises the transplant conversation at diagnosis or shortly after is giving the family information needed to make a time-sensitive decision.

Conclusion

Sickle cell disease is not a condition that patients simply endure between crises. It is a disease of continuous, cumulative damage to blood vessels, to organs, to the neurological development of children who miss school and cognitive milestones during repeated hospitalisations that progresses differently depending on how well it is managed across the whole year, not just during acute episodes. World Sickle Cell Day on June 19 is a reminder that awareness without access to specialist care changes very little for the individuals living with the disease. A best sickle cell specialist with the knowledge to implement hydroxyurea properly, screen for organ complications systematically, and know when to escalate to curative treatment; a sickle cell disease treatment with the protocols and multidisciplinary team to support that management; and referral access to an advanced haematology care hospital or top haematology hospital in Delhi NCR when transplant evaluation becomes the next step that is the system of care that changes outcomes. If you or a family member is managing SCD without that system around you, that is what today's awareness should prompt you to find.